{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:08:42Z","timestamp":1791727722084,"version":"4.3.4"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6S","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>Group B Streptococcus (GBS) is estimated to have caused 319,000 cases of neonatal disease resulting in 90,000 infant deaths globally in 2015. It is also associated with maternal sepsis, preterm births, stillbirths and neonatal encephalopathy. There is a significant burden of neurologic impairment among survivors of infant GBS disease. Intrapartum antibiotic prophylaxis strategies have reduced the incidence of newborn early-onset GBS (occurring days 0\u20136) in some settings, but they are not feasible in many low and middle-income countries. A maternal vaccine given to pregnant women to stimulate passive transplacental transfer of protective antibodies has the potential to reduce maternal disease, adverse pregnancy outcomes and newborn disease. Phase I and II vaccine studies are occurring, but conducting phase III efficacy studies of a GBS vaccine candidate would require very large numbers due to the relatively low incidence of invasive GBS disease. It has therefore been proposed that alternative pathways to vaccine licensure should be explored, for example, through use of a regulatory approved correlate of protection and safety evaluation in mothers, fetuses and infants. These studies would then be followed-up with post-licensure phase IV studies in which vaccine effectiveness is evaluated.<\/jats:p>","DOI":"10.1097\/inf.0000000000002328","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T03:40:57Z","timestamp":1560570057000},"page":"S72-S76","source":"Crossref","is-referenced-by-count":27,"title":["Group B Streptococcus: Trials and Tribulations"],"prefix":"10.1097","volume":"38","author":[{"given":"Hannah G.","family":"Davies","sequence":"first","affiliation":[{"name":"From the Paediatric Infectious Diseases Research Group, Institute of Infection & Immunity, St George\u2019s University of London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Carreras-Abad","sequence":"additional","affiliation":[{"name":"From the Paediatric Infectious Diseases Research Group, Institute of Infection & Immunity, St George\u2019s University of London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Le Doare","sequence":"additional","affiliation":[{"name":"From the Paediatric Infectious Diseases Research Group, Institute of Infection & Immunity, St George\u2019s University of London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T","family":"Heath","sequence":"additional","affiliation":[{"name":"From the Paediatric Infectious Diseases Research Group, Institute of Infection & Immunity, St George\u2019s University of London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-20230912","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1093\/cid\/cix658","article-title":"Maternal colonization with group B streptococcus and serotype distribution worldwide: systematic review and meta-analyses.","volume":"65","author":"Russell","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"R2-20230912","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/cid\/cix653","article-title":"Group B streptococcal disease worldwide for pregnant women, stillbirths, and children: why, what, and how to undertake estimates?","volume":"65","author":"Lawn","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"R3-20230912","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/cid\/cix656","article-title":"Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses.","volume":"65","author":"Madrid","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"R4-20230912","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1093\/cid\/cix664","article-title":"Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children.","volume":"65","author":"Seale","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"F4","DOI":"10.1136\/adc.2009.178483","article-title":"Empirical treatment of neonatal sepsis: are the current guidelines adequate?","volume":"96","author":"Muller-Pebody","year":"2011","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJMoa1005384","article-title":"Bacterial meningitis in the United States, 1998-2007.","volume":"364","author":"Thigpen","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1093\/cid\/ciu514","article-title":"Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United Kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance.","volume":"59","author":"Okike","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"RR-10","key":"R8-20230912","first-page":"1","article-title":"Prevention of perinatal group B streptococcal disease\u2013revised guidelines from CDC, 2010.","volume":"59","author":"Verani","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"suppl 2","key":"R9-20230912","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1093\/cid\/cix654","article-title":"Intrapartum antibiotic chemoprophylaxis policies for the prevention of group B streptococcal disease worldwide: systematic review.","volume":"65","author":"Le Doare","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R10-20230912","first-page":"CD007467","article-title":"Intrapartum antibiotics for known maternal Group B streptococcal colonization.","volume":"10","author":"Ohlsson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(15)00484-3","article-title":"Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.","volume":"16","author":"Heyderman","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"suppl 4","key":"R13-20230912","doi-asserted-by":"crossref","first-page":"D52","DOI":"10.1016\/j.vaccine.2013.02.029","article-title":"Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.","volume":"31","author":"Madhi","year":"2013","journal-title":"Vaccine"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/S1473-3099(17)30232-3","article-title":"Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis.","volume":"17","author":"Heath","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.12688\/f1000research.9363.1","article-title":"Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.","volume":"5","author":"Kobayashi","year":"2016","journal-title":"F1000Res"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJM197604012941404","article-title":"Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.","volume":"294","author":"Baker","year":"1976","journal-title":"N Engl J Med"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/422756","article-title":"Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen.","volume":"190","author":"Lin","year":"2004","journal-title":"J Infect Dis"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2015.10.019","article-title":"Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants.","volume":"33","author":"Dangor","year":"2015","journal-title":"Vaccine"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0022-3476(79)80530-2","article-title":"Epidemiology of the group B Streptococcus: maternal and nosocomial sources for infant acquisitions.","volume":"95","author":"Anthony","year":"1979","journal-title":"J Pediatr"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1542\/peds.68.4.544","article-title":"Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection.","volume":"68","author":"Baker","year":"1981","journal-title":"Pediatrics"},{"key":"R21-20230912","first-page":"198","article-title":"Risk factors for early-onset group B streptococcal disease in neonates: a population-based case-control study.","volume":"169","author":"Adair","year":"2003","journal-title":"CMAJ"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0002-9378(80)90382-8","article-title":"The natural history of group B streptococcal colonization in the pregnant woman and her offspring. I. Colonization studies.","volume":"137","author":"Yow","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0022-3476(78)80623-4","article-title":"Early onset group B streptococcal disease.","volume":"93","author":"Baker","year":"1978","journal-title":"J Pediatr"},{"issue":"suppl 1","key":"R24-20230912","first-page":"A2","article-title":"Group B Streptococcal (GBS) disease in UK and Irish infants younger than 90 days, 2014\u20132015.","volume":"101","author":"O\u2019Sullivan","year":"2016","journal-title":"Arch Dis Child"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1086\/376457","article-title":"Prematurity is the major risk factor for late-onset group B streptococcus disease.","volume":"188","author":"Lin","year":"2003","journal-title":"J Infect Dis"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jpids\/piv067","article-title":"Risk factors for late-onset group B streptococcal disease before and after implementation of universal screening and intrapartum antibiotic prophylaxis.","volume":"5","author":"Pintye","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3201\/eid2104.141562","article-title":"Increased risk for group B Streptococcus sepsis in young infants exposed to HIV, Soweto, South Africa, 2004\u20132008(1).","volume":"21","author":"Cutland","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"suppl 2","key":"R28-20230912","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1093\/cid\/cix663","article-title":"Neurodevelopmental impairment in children after group B streptococcal disease worldwide: systematic review and meta-analyses.","volume":"65","author":"Kohli-Lynch","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1111\/1471-0528.14821","article-title":"Prevention of Early-onset Neonatal Group B Streptococcal Disease: Green-top Guideline No. 36.","volume":"124","year":"2017","journal-title":"BJOG"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa020205","article-title":"A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates.","volume":"347","author":"Schrag","year":"2002","journal-title":"N Engl J Med"},{"key":"R31-20230912","first-page":"83","article-title":"Group B streptococcal (GBS) disease in UK and Irish infants younger than 90 days, 2014\u20132015: results from prospective surveillance.","volume":"19","author":"O\u2019Sullivan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"e98778","DOI":"10.1371\/journal.pone.0098778","article-title":"Serotype-specific acquisition and loss of group B streptococcus recto-vaginal colonization in late pregnancy.","volume":"9","author":"Kwatra","year":"2014","journal-title":"PLoS One"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1471-0528.2005.00555.x","article-title":"Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease.","volume":"112","author":"Akker-van Marle","year":"2005","journal-title":"BJOG"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3109\/14767058.2013.818128","article-title":"Real-time PCR-assay in the delivery suite for determination of group B streptococcal colonization in a setting with risk-based antibiotic prophylaxis.","volume":"27","author":"H\u00e5kansson","year":"2014","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/14767058.2014.934804","article-title":"Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference.","volume":"28","author":"Di Renzo","year":"2015","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1056\/NEJMoa0806820","article-title":"Evaluation of universal antenatal screening for group B streptococcus.","volume":"360","author":"Van Dyke","year":"2009","journal-title":"N Engl J Med"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1128\/AAC.00185-08","article-title":"First molecular characterization of group B streptococci with reduced penicillin susceptibility.","volume":"52","author":"Kimura","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.anai.2009.11.005","article-title":"Anaphylaxis in the obstetric patient: analysis of a statewide hospital discharge database.","volume":"104","author":"Mulla","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"suppl","key":"R39-20230912","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.jinf.2016.04.026","article-title":"Recognising early onset neonatal sepsis: an essential step in appropriate antimicrobial use.","volume":"72","author":"van Herk","year":"2016","journal-title":"J Infect"},{"key":"R40-20230912","article-title":"WHO consultation on group B Streptococcus vaccine development: report from a meeting held on 27\u201328 April 2016.","author":"Kobayashi","year":"2016","journal-title":"Vaccine"},{"key":"R41-20230912","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(14)60236-1","article-title":"Maternal and neonatal tetanus.","volume":"385","author":"Thwaites","year":"2015","journal-title":"Lancet"},{"key":"R42-20230912","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0140-6736(14)60686-3","article-title":"Effectiveness of maternal pertussis vaccination in England: an observational study.","volume":"384","author":"Amirthalingam","year":"2014","journal-title":"Lancet"},{"key":"R43-20230912","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa1401480","article-title":"Influenza vaccination of pregnant women and protection of their infants.","volume":"371","author":"Madhi","year":"2014","journal-title":"N Engl J Med"},{"key":"R44-20230912","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/17460913.4.2.201","article-title":"Understanding the regulation of Group B Streptococcal virulence factors.","volume":"4","author":"Rajagopal","year":"2009","journal-title":"Future Microbiol"},{"key":"R45-20230912","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3410\/B2-36","article-title":"Bacterial surface proteins and vaccines.","volume":"2","author":"Grandi","year":"2010","journal-title":"F1000 Biol Rep"},{"key":"R46-20230912","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/fty016","article-title":"Protein adhesins as vaccine antigens for Group A Streptococcus.","volume":"76","author":"Raynes","year":"2018","journal-title":"Pathog Dis"},{"key":"R47-20230912","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/S0264-410X(03)00353-0","article-title":"Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine.","volume":"21","author":"Baker","year":"2003","journal-title":"Vaccine"},{"key":"R48-20230912","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/siny.2002.0114","article-title":"Vaccines to prevent neonatal GBS infection.","volume":"7","author":"Paoletti","year":"2002","journal-title":"Semin Neonatol"},{"key":"R49-20230912","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/2051013615579869","article-title":"Group B Streptococcus vaccine: state of the art.","volume":"3","author":"Nuccitelli","year":"2015","journal-title":"Ther Adv Vaccines"},{"key":"R50-20230912","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7774\/cevr.2018.7.1.76","article-title":"Status of group B streptococcal vaccine development.","volume":"7","author":"Lin","year":"2018","journal-title":"Clin Exp Vaccine Res"},{"key":"R51-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2018.1493326","article-title":"Progress toward a group B streptococcal vaccine.","volume":"14","author":"Song","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"R52-20230912","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1016\/j.vaccine.2018.09.058","article-title":"Cost-effectiveness analysis of maternal immunisation against Group B Streptococcus (GBS) disease: a modelling study.","volume":"36","author":"Giorgakoudi","year":"2018","journal-title":"Vaccine"},{"key":"R53-20230912","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1016\/j.vaccine.2014.06.003","article-title":"Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?","volume":"32","author":"Oster","year":"2014","journal-title":"Vaccine"},{"key":"R54-20230912","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.vaccine.2014.01.062","article-title":"Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa.","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"issue":"49 pt B","key":"R55-20230912","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1016\/j.vaccine.2017.07.108","article-title":"Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa.","volume":"35","author":"Russell","year":"2017","journal-title":"Vaccine"},{"key":"R56-20230912","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/14760584.2014.953939","article-title":"Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants.","volume":"14","author":"Dangor","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"R57-20230912","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1586\/14760584.2015.1085307","article-title":"Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants.","volume":"14","author":"Dangor","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"R58-20230912","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/21645515.2017.1377379","article-title":"Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.","volume":"14","author":"Choi","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"R59-20230912","article-title":"Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics.","author":"Vekemans","year":"2018","journal-title":"Vaccine"},{"key":"R60-20230912","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1542\/peds.2011-3453","article-title":"Long-term outcomes of group B streptococcal meningitis.","volume":"130","author":"Libster","year":"2012","journal-title":"Pediatrics"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201906001-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:17:23Z","timestamp":1694557043000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201906001-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":59,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002328","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}